Long noncoding RNA NORAD regulates cancer cell proliferation and migration in human osteosarcoma by endogenously...

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Osteosarcoma is a primary bone malignancy with limited treatment options.
• Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.
• NORAD (Noncoding RNA activated by DNA damage) is a lncRNA implicated in various cancers.

Purpose of the Study:

• To investigate the expression and function of NORAD in human osteosarcoma.
• To elucidate the molecular mechanism underlying NORAD's role in osteosarcoma progression.
• To assess NORAD as a potential therapeutic target for osteosarcoma.

Main Methods:

• Quantitative real-time PCR (qRT-PCR) for NORAD expression analysis in cell lines and patient tumors.
• siRNA-mediated NORAD downregulation in osteosarcoma cells (Saos-2, 143B).
• Functional assays including CCK-8 proliferation, Transwell invasion, and in vivo tumor explant studies.
• Dual-luciferase reporter assay and qRT-PCR to confirm NORAD-hsa-miR-199a-3p interaction.

Main Results:

• NORAD was significantly overexpressed in osteosarcoma cell lines and clinical specimens.
• NORAD downregulation suppressed osteosarcoma cell proliferation, invasion, and in vivo tumor growth.
• NORAD was confirmed to competitively bind hsa-miR-199a-3p.
• Downregulation of hsa-miR-199a-3p reversed the tumor-suppressive effects of NORAD inhibition.

Conclusions:

• NORAD plays a crucial oncogenic role in osteosarcoma by promoting cell proliferation and invasion.
• The NORAD/hsa-miR-199a-3p axis is a key regulatory pathway in osteosarcoma.
• NORAD represents a promising therapeutic target for osteosarcoma treatment.